Skip to main content

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Project description

Next-generation topical medication for the treatment of eczema

Atopic dermatitis, or eczema, is a chronic skin condition that is common in children but may occur at any age. It arises as a result of a complex interaction between genetic and environmental factors and poses a significant burden on patients’ quality of life. Itch is an enormous, unresolved symptom in atopic dermatitis, induced by inflammation and skin damage. Sweden's TIRmed Pharma AB has developed a non-steroid cream to resolve itch with topical application. The medication targets mild to moderate symptoms, has an excellent safety profile and is affordable and easy to self-apply. Moreover, as the solution interferes with the immune system in a selective manner, it dampens inflammation. The EU-funded TIR-C project proposes a feasibility study, the development of a commercialisation plan and the confirmation of the regulatory requirements needed for market approvals.

Field of science

  • /medical and health sciences/clinical medicine/dermatology

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

TIRMED PHARMA AB
Address
Spets Alviksvagen 1
16753 Bromma
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000